利奈唑胺组织穿透性及在感染组织中的药效学

摘要/Abstract

摘要： 利奈唑胺对革兰阳性(G⁺)菌抗菌作用强,具有较好的药代动力学特征,组织穿透性好,血浆或血清中＞50%利奈唑胺可以穿透到感染组织,在不同感染组织针对不同病原菌PK/PD参数有所不同,中国人群利奈唑胺敏感菌最小抑菌浓度(MIC)为 0.5~2 μg/mL,对特定病原菌具有抗生素后效应,是治疗G⁺菌感染的糖肽类多重耐药的最后防线。本文就利奈唑胺针对G⁺菌感染治疗的组织穿透性及在感染组织中的药效动力学作一综述,为临床合理选用利奈唑胺提供参考。

关键词: 利奈唑胺, 组织穿透性, 最小抑菌浓度, 抗生素后效应, PK/PD参数

Abstract: Linezolid has strong antibacterial activities for G⁺ infection and perfect pharmacokinetics and tissue penetration, more than 50% plasma (or serum) concentration of linezolid was detected in the infected tissues. Different PK/PD parameters was found according to different pathogens and different infected tissues. The MIC value of linezolid for susceptible bacteria was 0.5-2 μg/mL.The post-antibiotic effect of linezolid was found in some specific bacteria. Linezolid can be used as the most solid barriers in the treatment of multiresistant G⁺ infection. The tissue penetration and pharmacodynamics characteristics of linezolid in the treatment of G⁺ infection is summarized, which can help healthy providers decide how to use linezolid in the treament of G⁺ infections.

Key words: linezolid, tissue penetration, MIC, post-antibiotic effect, PK/PD parameters

中图分类号:

R969

李春杏, 付强, 朱珠. 利奈唑胺组织穿透性及在感染组织中的药效学[J]. 中国临床药理学与治疗学, 2015, 20(3): 349-355.

LI Chun-xing, FU Qiang, ZHU Zhu. The tissue penetration and pharmacodynamics of linezolid in the infected tissues[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 349-355.

参考文献

[1] Paladino JA. Linezolid: An oxazolidinone antimicrobial agent[J]. Am J Health Syst Pharm, 2002,59(24):2413-2425.
[2] MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections[J]. J Antimicrob Chemother, 2003,51(Suppl 2): ii17-25.
[3] Delman DM, Rasmussen SA, Beigi RH, et al. Prophylaxis and treatment of anthrax in pregnant women[J]. Obstet Gynecol, 2013,122(4):885-900.
[4] 2013 Truven Health Analytics Inc. MICROMEDEX(R) Healthcare Series Vol. 158 expires 12/2013.
[5] Bogard KN, Peterson NT, Plumb TJ, et al. Antibiotic dosing during sustained low-efficiency dialysis: Special considerations in adult critically ill patients[J]. Crit Care Med, 2011,39(3):560-570.
[6] Mauro LS, Peloquin CA, Schmude K, et al. Clearance of linezolid via continuous venovenous hemodiafiltration[J]. Am J Kidney Dis, 2006,47(6): E83-E86.
[7] Bhalodi AA, Papasavas PK, Tishler DS, et al. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults[J]. Antimicrob Agents Chemother, 2013,57(3):1144-1149.
[8] Viaggi B, Paolo AD, Danesi R, et al. Linezolid in the central nervous system: Comparison between cerebrospinal fluid and plasma pharmacokinetics[J]. Scand J Infect Dis, 2011,43(9):721-727.
[9] Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains[J]. Antimicrob Agents Chemother, 2007,50(1):379-382.
[10]Majcher-Peszynska J, Haase G, Mundkowski R, et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections[J]. Eur J Clin Pharmacol, 2008,64(11):1093-1100.
[11]Dehghanyar P, Burger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses[J]. Antimicrob Agents Chemother, 2005,49(6):2367-2371.
[12]Rana B, Butcher I, Grigoris P, et al. Linezolid penetration into osteo-articular tissues[J]. J Antimicrob Chemother, 2002,50(5):747-750.
[13]Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses[J]. Antimicrob Agents Chemother, 2001,45(6):1843-1846.
[14]Conte JE, Golden JA, Kips A, et al. Intrapulmonary pharmacokinetics of inezolid[J]. Antimicrob Agents Chemother, 2002,46(5):1475-1480.
[15]Pea F, Lugarno M, Baccarani U, et al. Biliary pharmacodynamic exposure to linezolid in two liver transplant patients[J]. J Antimicrob Chemother, 2014, 69(2):567-568.
[16]Vaázquez EG, Mensa J, Loópez Y, et al. Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration[J]. Antimicrob Agents Chemother, 2004,48(2): 670-672.
[17]George JM, Fiscella R, Blair M, et al. Aqueous and Vitreous Penetration of Linezolid and Levofloxacin After Oral Administration[J]. J Ocul Pharmacol Ther, 2010,26(6):579-586.
[18]Hosgor-Limoncu M, Ermertcan S, Tasli H, et al. The post-antibiotic effects of linezolid against Gram-positive pathogens[J]. Saudi Med J, 2007,28(4):551-554.
[19]Athamna A, Athamna M, Medlej B, et al. In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis[J]. J Antimicrob Chemother, 2004,53(4):609-615.
[20]李耘,吕媛,薛峰,等. 卫生部全国细菌耐药监测网(Mohnarin)2011-2012年革兰阳性菌耐药监测报告[J]. 中国临床药理学杂志,2014,30(3):251-259.
[21]Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme[J]. Clin Pharmacokinet, 2003,42(15):1411-1423.
[22]Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis[J]. Antimicrob Agents Chemother, 2004,48(1):281-284.
[23]Ramsey TD, Lau TT, Ensom MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach[J]. Ann Pharmacother, 2013,47(4):543-560.
[24]Bolhuis MS, Altena RV, Soolingen DV, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients[J]. Eur Respir J, 2013,42(6):1614-1621.
[25]Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin[J]. Pharmacotherapy, 2007,27(3):476-479.
[26]邱海波. PK／PD与抗菌药物合理[A]. 第二届中国急救急诊医师行业学术年会暨国家级突发公共事件医学救援大会《专家报告集》[C].长春,2007:37-43.
[27]Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion[J]. Int J Antimicrob Agents, 2008,31(2):122-129.
[28]尹红,蔡芸,白楠,等. 利奈唑胺不同速度单次静滴在中国健康成年志愿者的耐受性[J]. 中国临床药理学杂志,2011,27(2):107-109.
[29]Lovering AM, Floch R, Hovsepian L, et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries[J]. J Antimicrob Chemother, 2009,63(3):553-559.